Table 3.
Adverse events resulting in dose reduction (DR) or discontinuation (DC) of therapy.
| Adverse events | N | Grade | Attribution | Intervention | ||
|---|---|---|---|---|---|---|
| Everolimus | Bevacizumab | Everolimus | Bevacizumab | |||
| Abdomen hemorrhage | 1 | 5 | − | + | DC | DC |
| Alanine aminotransferase | 1 | 3 | + | − | DC | DC |
| Proteinuria | 1 | 2 | − | + | DC | DC |
| Proteinuria∗ | 1 | 1 | − | + | DC | DC |
| Neurologic decline∗ | 1 | 3 | − | − | DC | DC |
| Back pain | 1 | 2 | − | − | DC | DC |
| Pain∗ | 1 | 4 | − | − | DC | DC |
| Thromboembolism | 1 | 3 | − | − | None | DC |
| Fatigue | 1 | 3 | + | + | DR | None |
| Mucositis | 2 | 2 | + | − | DR | None |
| Mucositis | 1 | 1 | + | − | DR | None |
| Ear pain | 1 | 1 | + | − | DR | None |
∗Off-treatment reason for these patients was disease progression.